SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514.
AMSTERDAM, THE NETHERLANDS, 29 July 2024. SERDA Therapeutics, a biopharmaceutical company focused on developing improved treatments for burns and chronic wounds, today announced completion of its first Phase 1 human clinical study of SN514 hydrogel, an innovative enzymatic wound debriding agent, in healthy adult volunteers. In preclinical studies, SN514 hydrogel showed outstanding efficacy and speed […]
SERDA Therapeutics Announces Initiation of Phase 1 Clinical Study of SN514
AMSTERDAM, THE NETHERLANDS, 03 June 2024. SERDA Therapeutics, a biopharmaceutical company focused on developing improved treatments for burns and chronic wounds, today announced initiation of its first Phase 1 human clinical study of SN514 hydrogel, an innovative enzymatic wound debriding agent, in healthy adult volunteers. SN514 hydrogel is a topical debridement product designed to remove […]
SERDA Therapeutics completes a € 2 Million funding round to develop an innovative enzymatic wound debridement product
Following a successful IND submission, The Dutch health venture SERDA Therapeutics has raised € 2 million in a funding round led by NLC Health Impact Fund. The infusion of new capital will be used to complete Phase I / IIa clinical studies with the company’s innovative wound debridement product SN514. SERDA Therapeutics is developing a […]